Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells.
BMC Complement Altern Med
; 13: 185, 2013 Jul 19.
Article
em En
| MEDLINE
| ID: mdl-23870199
ABSTRACT
BACKGROUND:
Hepatocellular carcinoma (HCC) is a common and aggressive cancer, and the treatment options are limited for patients with advanced HCC. Bufalin, the major digoxin-like component of the traditional Chinese medicine Chansu, exhibits significant anti-tumor activities in many tumor cell lines. In the present study, we investigated the effect of bufalin on the inhibition of an AKT-related signaling pathway, and examined the relationship between regulatory proteins and anti-tumor effects in hepatoma cells.METHODS:
Proliferation, wound healing, transwell-migration/invasion and adhesion assays were performed in HCCLM3 and HepG2 cell lines. The protein levels of pAKT, AKT, pGSK3ß, GSK3ß, pß-catenin, ß-catenin, E-cadherin, MMP-9, and MMP-2 were measured by western blot analysis. E-Cadherin and ß-catenin expression levels were also evaluated by immunofluorescence.RESULTS:
Bufalin inhibited hepatoma cell proliferation, migration, invasion and adhesion. In addition, treatment with bufalin significantly decreased the levels of pAKT, pGSK3ß, MMP-9, and MMP-2, while increasing the levels of GSK3ß and E-cadherin and suppressing the nuclear translocation of ß-catenin.CONCLUSIONS:
Bufalin is a potential anti-HCC therapeutic candidate through its inhibition of the AKT/GSK3ß/ß-catenin/E-cadherin signaling pathway. Further studies with bufalin are warranted in patients with HCC, especially those with the disease at advanced stages.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Bufanolídeos
/
Carcinoma Hepatocelular
/
Proliferação de Células
/
Neoplasias Hepáticas
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
BMC Complement Altern Med
Assunto da revista:
TERAPIAS COMPLEMENTARES
Ano de publicação:
2013
Tipo de documento:
Article